Abstract 343P
Background
Palonosetron was greater than first-generation 5-HT3 receptor antagonists in the prevention of nausea and vomiting have been established in many systematic reviews. However, several recent randomized control trials manifested inconsistent results. Thus, we conducted a systematic review to evaluate the efficacy and safety of palonosetron versus granisetron in chemotherapy induced nausea and vomiting (CINV).
Methods
The PubMed, Embase, and The Cochrane Library databases were searched for studies published before April 2020. The meta-analysis was performed to estimate the pooled effect sizes by using a random effect model. The primary outcome was treatment responses of CINV (complete response rate, complete control rate, and total control rate). Secondary outcomes were 5-HT3 receptor antagonist related common side effects (constipation, and headache).
Results
Twelve randomized controlled trials, three prospective studies and one retrospective study were reviewed. Palonosetron was consistently statistically superior in any phase of complete response rate (acute phases: odds ratio [OR]= 1.37, 95% confidence interval [CI]: 1.03 to 1.82; delayed phases: OR= 1.57, 95% CI: 1.15 to 2.15; overall phases: OR= 1.37, 95% CI: 1.17 to 1.60), delayed phases of complete control rate and total control rate (OR= 1.45, 95% CI: 1.23 to 1.72; OR= 1.29, 95% CI: 1.01 to 1.65, respectively). Subgroup analysis indicated that there was no significant difference between palonosetron and granisetron in any phase of complete response when combined with NK1 antagonists. No statistically significant difference was found between constipation and diarrhea toxicities of the two groups.
Conclusions
Although palonosetron significantly decreased the risk of chemotherapy induced nausea and vomiting in any phase, granisetron is seeming comparable effectiveness with palonosetron when adding NK1 antagonists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
312P - Identification of neoantigen-specific T cell response and anti-tumour immunity in pancreatic cancer
Presenter: Xiaoxiao Du
Session: e-Poster Display Session
313P - Diagnostic value of micro RNA (miRNA) in renal cell cancer: A meta-analysis and systemic review
Presenter: Jestoni Aranilla
Session: e-Poster Display Session
314P - Comprehensive microbial signatures and genomic profiling in tumour samples using next generation sequencing
Presenter: Mei Qi Yee
Session: e-Poster Display Session
315P - High-penetrance breast and/or ovarian cancer susceptibility genes in Filipinos
Presenter: Frances Victoria Que
Session: e-Poster Display Session
316P - Implementation of Vela Analytics to accelerate comprehensive interpretation and reporting of next-generation sequencing-based oncology testing in clinical diagnostic laboratories
Presenter: Yingnan Yu
Session: e-Poster Display Session
317P - Genomic profiling and molecular pathology of Chinese glioma patients
Presenter: yuanli Zhao
Session: e-Poster Display Session
320P - Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies
Presenter: Kelvin Bao
Session: e-Poster Display Session
321P - Impact of COVID-19 and lockdown on adherence to treatment schedule among cancer patients
Presenter: Krishnamani Kalpathi
Session: e-Poster Display Session
322P - Challenged faced by cancer patients during the COVID-19 pandemic
Presenter: mithra Krishnamani
Session: e-Poster Display Session
323P - Oncology care in the Republic of Kazakhstan during COVID-19
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session